The clinical potential of sphingolipid-based therapeutics

Cellular and Molecular Life Sciences

Volumn 63, Issue 9, 2006, Pages 1017-1023

  Fox, T E ^a   Finnegan, C M ^b   Blumenthal, R ^b   Kester, M ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ceramide; Immunity; Infectivity; Inflammation; Sphingolipids; Therapeutics

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSYLCERAMIDE; CERAMIDE; CYCLOSPORIN A; FENRETINIDE; FINGOLIMOD; FUMONISIN B1; KRN 700; MIGLUSTAT; SAFINGOL; SPHINGOLIPID; THERMOZYMOCIDIN;

ALLERGIC ENCEPHALOMYELITIS; ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; ATHEROSCLEROSIS; CLINICAL TRIAL; COLITIS; DRUG MECHANISM; EMPHYSEMA; ENVIRONMENTAL FACTOR; FABRY DISEASE; GAUCHER DISEASE; GRAFT REJECTION; HOMEOSTASIS; HUMAN; LIPID METABOLISM; LUNG FIBROSIS; METABOLIC REGULATION; NIEMANN PICK DISEASE; NONHUMAN; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; STIMULUS RESPONSE;

ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; CERAMIDES; COMMUNICABLE DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; SPHINGOLIPIDS;

EID: 33744471640     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-005-5543-z     Document Type: Review

References (75)

1. Futerman A. H. and Hannun Y. A. (2004) The complex life of simple sphingolipids. EMBO Rep. 5: 777-782
2. Kester M. and Kolesnick R. (2003) Sphingolipids as therapeutics. Pharmacol. Res. 47: 365-371
3. Ruvolo P. P. (2003) Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol. Res. 47: 383-392
4. Hannun Y. A. and Obeid L. M. (2002) The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 277: 25847-25850
5. Goni F. M., Contreras F. X., Montes L. R., Sot J. and Alonso A. (2005) Biophysics (and sociology) of ceramides. Biochem. Soc. Symp. 177-188
6. Cremesti A. E., Goni F. M. and Kolesnick R. (2002) Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome? FEBS Lett. 531: 47-53
7. Kronke M. (1999) Biophysics of ceramide signaling: interaction with proteins and phase transition of membranes. Chem. Phys. Lipids. 101: 109-121
8. Futerman A. H. and Riezman H. (2005) The ins and outs of sphingolipid synthesis. Trends Cell Biol. 15: 312-318
9. Cuvillier O., Pirianov G., Kleuser B., Vanek P. G., Coso O. A., Gutkind S. et al. (1996) Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381: 800-803
10. Jmoudiak M. and Futerman A. H. (2005) Gaucher disease: pathological mechanisms and modern management. Br. J. Haematol. 129: 178-188
11. Futerman A. H. and van Meer G. (2004) The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 5: 554-565
12. Miranda S. R., He X., Simonaro C. M., Gatt S., Dagan A., Desnick R. J. et al. (2000) Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 14: 1988-1995
13. Hojjati M. R., Li Z., Zhou H., Tang S., Huan C., Ooi E. et al. (2005) Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J. Biol. Chem. 280: 10284-10289
14. Petrache I., Natarajan V., Zhen L., Medler T. R., Richter A. T., Cho C. et al. (2005) Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat. Med. 11: 491-498
15. Hwang D., Popat R., Bragdon C., O'Donnell K. E. and Sonis S. T. (2005) Effects of ceramide inhibition on experimental radiation-induced oral mucositis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 100: 321-329
16. Reynolds C. P., Maurer B. J. and Kolesnick R. N. (2004) Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 206: 169-180
17. Miyake S. and Yamamura T. (2005) Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord. 5: 315-322
18. Berkers C. R. and Ovaa H. (2005) Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol. Sci. 26: 252-257
19. Tedesco-Silva H., Mourad G., Kahan B. D., Boira J. G., Weimar W., Mulgaonkar S. et al. (2004) FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 77: 1826-1833
20. Webb M., Tham C. S., Lin F. F., Lariosa-Willingham K., Yu N., Hale J. et al. (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 153: 108-121
21. Rausch M., Hiestand P., Foster C. A., Baumann D. R., Cannet C. and Rudin M. (2004) Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 20: 16-24
22. Fujino M., Funeshima N., Kitazawa Y., Kimura H., Amemiya H., Suzuki S. et al. (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 305: 70-77
23. Maki T., Gottschalk R., Ogawa N. and Monaco A. P. (2005) Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation 79: 1051-1055
24. Fu F., Hu S., Deleo J., Li S., Hopf C., Hoover J. et al. (2002) Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation 73: 1425-1430
25. Wijkstrom M., Kenyon N. S., Kirchhof N., Kenyon N. M., Mullon C., Lake P. et al. (2004) Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD and FTY720. Transplantation 77: 827-835
26. Morecki S., Panigrahi S., Pizov G., Yacovlev E., Gelfand Y., Eizik O. et al. (2004) Effect of KRN7000 on induced graft-vs-host disease. Exp. Hematol. 32: 630-037
27. Kimura T., Ishii Y., Morishima Y., Shibuya A., Shibuya K., Taniguchi M. et al. (2004) Treatment with alpha-galactosylceramide attenuates the development of bleomycin-induced pulmonary fibrosis. J. Immunol. 172: 5782-5789
28. Kobayashi E., Motoki K., Uchida T., Fukushima H. and Koezuka Y. (1995) KRN7000, a novel immunomodulator and its antitumor activities. Oncol. Res. 7: 529-534
29. Ishikawa A., Motohashi S., Ishikawa E., Fuchida H., Higashino K., Otsuji M. et al. (2005) A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11: 1910-1917
30. Miyamoto K., Miyake S. and Yamamura T. (2001) A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413: 531-534
31. Chiba A., Oki S., Miyamoto K., Hashimoto H., Yamamura T. and Miyake S. (2004) Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum. 50: 305-313
32. Ueno Y., Tanaka S., Sumii M., Miyake S., Tazuma S., Taniguchi M. et al. (2005) Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of valpha14 natural killer T cells in mice. Inflamm. Bowel Dis. 11: 35-41
33. Mizuno M., Masumura M., Tomi C., Chiba A., Oki S., Yamamura T. et al. (2004) Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J. Autoimmun. 23: 293-300
34. Zemann B., Kinzel B., Muller M., Reuschel R., Mechtcheriakova D., Urtz N. et al. (2005) Sphingosine kinase type 2 is essential for lymphodepletion induced by the immunomodulatory drug FTY720. Blood [Epub, ahead of print]
35. Bandhuvula P., Tam Y. Y., Oskouian B. and Saba J. D. (2005) The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J. Biol. Chem. 280: 33697-33700
36. Turinsky J., O'Sullivan D. M. and Bayly B. P. (1990) 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J. Biol. Chem. 265: 16880-16885
37. Gorska M., Dobrzyn A., Zendzian-Piotrowska M. and Gorski J. (2004) Effect of streptozotocin-diabetes on the functioning of the sphingomyelin-signalling pathway in skeletal muscles of the rat. Horm. Metab. Res. 36: 14-21
38. Straczkowski M., Kowalska I., Nikolajuk A., Dzienis-Straczkowska S., Kinalska I., Baranowski M. et al. (2004) Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 53: 1215-1221
39. Adams J. M. 2nd, Pratipanawatr T., Berria R., Wang E., De-Fronzo R. A., Sullards M. C. et al. (2004) Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53: 25-31
40. Summers S. A. and Nelson D. H. (2005) A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X and Cushing's syndrome. Diabetes 54: 591-602
41. Tagami S., Inokuchi Ji J., Kabayama K., Yoshimura H., Kitamura F., Uemura S. et al. (2002) Ganglioside GM3 participates in the pathological conditions of insulin resistance. J. Biol. Chem. 277: 3085-3092
42. Kabayama K., Sato T., Kitamura F., Uemura S., Kang B. W., Igarashi Y. et al. (2005) TNFalpha-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3. Glycobiology 15: 21-29
43. Zador I. Z., Deshmukh G. D., Kunkel R., Johnson K., Radin N. S. and Shayman J. A. (1993) A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J. Clin. Invest. 91: 797-803
44. Masson E., Troncy L., Ruggiero D., Wiernsperger N., Lagarde M. and Bawab S. E. (2005) a-Series gangliosides mediate the effects of advanced glycation end products on pericyte and mesangial cell proliferation: a common mediator for retinal and renal microangiopathy? Diabetes 54: 220-227
45. Wang L., Xing X. P., Holmes A., Wadham C., Gamble J. R., Vadas M. A. et al. (2005) Activation of the sphingosine kinase-signaling pathway by high glucose mediates the proinflammatory phenotype of endothelial cells. Circ. Res. 97: 891-899
46. Geoffroy K., Troncy L., Wiernsperger N., Lagarde M. and El Bawab S. (2005) Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett. 579: 1249-1254
47. Baumruker T., Bornancin F. and Billich A. (2005) The role of sphingosine and ceramide kinases in inflammatory responses. Immunol. Lett. 96: 175-185
48. Kee T. H., Vit P. and Melendez A. J. (2005) Sphingosine kinase signalling in immune cells. Clin. Exp. Pharmacol Physiol. 32: 153-161
49. Hinkovska-Galcheva V., Boxer L. A., Kindzelskii A., Hiraoka M., Abe A., Goparju S. et al. (2005) Ceramide 1-phosphate, a mediator of phagocytosis. J. Biol. Chem. 280: 26612-26621
50. Subramanian P., Stahelin R. V., Szulc Z., Bielawska A., Cho W. and Chalfant C. E. (2005) Ceramide 1-phosphate acts as a positive allosteric activator of group IVA cytosolic phospholipase A2 alpha and enhances the interaction of the enzyme with phosphatidylcholine. J. Biol. Chem. 280: 17601-17607
51. Pettus B. J., Kitatani K., Chalfant C. E., Taha T. A., Kawamori T., Bielawski J. et al. (2005) The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate. Mol. Pharmacol. 68: 330-335
52. Tuson M., Marfany G. and Gonzalez-Duarte R. (2004) Mutation of CERKL, a novel human ceramide kinase gene, causes autosomal recessive retinitis pigmentosa (RP26). Am. J. Hum. Genet. 74: 128-138
53. Bornancin F., Mechtcheriakova D., Stora S., Graf C., Wlachos A., Devay P. et al. (2005) Characterization of a ceramide kinase-like protein. Biochim. Biophys. Acta 1687: 31-43
54. Acharya U., Patel S., Koundakjian E., Nagashima K., Han X. and Acharya J. K. (2003) Modulating sphingolipid biosynthetic pathway rescues photoreceptor degeneration. Science 299: 1740-1743
55. Grassme H., Gulbins E., Brenner B., Ferlinz K., Sandhoff K., Harzer K. et al. (1997) Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell 91: 605-615
56. Hauck C. R., Grassme H., Bock J., Jendrossek V., Ferlinz K., Meyer T. F. et al. (2000) Acid sphingomyelinase is involved in CEACAM receptor-mediated phagocytosis of Neisseria gonorrhoeae. FEBS Lett. 478: 260-266
57. Grassme H., Jendrossek V., Riehle A., von Kurthy G., Berger J., Schwarz H. et al. (2003) Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 9: 322-330
58. Esen M., Schreiner B., Jendrossek V., Lang F., Fassbender K., Grassme H. et al. (2001) Mechanisms of Staphylococcus aureus induced apoptosis of human endothelial cells. Apoptosis 6: 431-439
59. Hanada K., Mitamura T., Fukasawa M., Magistrado P. A., Horii T. and Nishijima M. (2000) Neutral sphingomyelinase activity dependent on Mg2+ and anionic phospholipids in the intraerythrocytic malaria parasite Plasmodium falciparum. Biochem. J. 346:671-677
60. Jan J. T., Chatterjee S. and Griffin D. E. (2000) Sindbis virus entry into cells triggers apoptosis by activating sphingomyelinase, leading to the release of ceramide. J. Virol. 74: 6425-6432
61. Grassme H., Riehle A., Wilker B. and Gulbins E. (2005) Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms. J. Biol. Chem. 280: 26256-26262
62. Finnegan C. M., Rawat S. S., Puri A., Wang J. M., Ruscetti F. W. and Blumenthal R. (2004) Ceramide, a target for antiretroviral therapy. Proc. Natl. Acad. Sci. USA 101: 15452-15457
63. Finnegan C. M. and Blumenthal R. (2005) Fenretinide inhibits HIV infection by promoting viral endocytosis. Antiviral. Res. [Epub, ahead of print]
64. Gallo S. A., Finnegan C. M., Viard M., Raviv Y., Dimitrov A., Rawat S. S. et al. (2003) The HIV Env-mediated fusion reaction. Biochim. Biophys. Acta 1614: 36-50
65. Rawat S. S., Johnson B. T. and Puri A. (2005) Sphingolipids: modulators of HIV-1 infection and pathogenesis. Biosci. Rep. 25: 329-343
66. Stover T. and Kester M. (2003) Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J. Pharmacol. Exp. Ther. 307: 468-475
67. Shabbits J. A. and Mayer L. D. (2003) Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta 1612: 98-106
68. Shabbits J. A. and Mayer L. D. (2003) High ceramide content liposomes with in vivo antitumor activity. Anticancer. Res. 23: 3663-3669
69. Stover T. C., Sharma A., Robertson G. P. and Kester M. (2005) Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res. 11: 3465-3474
70. Muro S., Schuchman E. H. and Muzykantov V. R. (2006) Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol. Ther. 13: 135-141
71. Rossi M. J., Sundararaj K., Koybasi S., Phillips M. S., Szulc Z. M., Bielawska A. et al. (2005) Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells. Otolaryngol. Head Neck Surg. 132: 55-62
72. Novgorodov S. A., Szulc Z. M., Luberto C., Jones J. A., Bielawski J., Bielawska A. et al. (2005) Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J. Biol. Chem. 280: 16096-16105
73. Dagan A., Wang C., Fibach E. and Gatt S. (2003) Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death. Biochim. Biophys. Acta 1633: 161-169
74. Darroch P. I., Dagan A., Granot T., He X., Gatt S. and Schuchman E. H. (2005) A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide and leads to cell death. J. Lipid. Res. 46: 2315-2324
75. French K. J., Schrecengost R. S., Lee B. D., Zhuang Y., Smith S. N., Eberly J. L. et al. (2003) Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63: 5962-5969